Clinical and laboratory features of patients with acquired hemophilia treated by MBMP
Patient . | Age, y . | Sex . | Titer, BU . | Bleeding events . | Length of hospital stay, d . | FVIII × 106, IU . | rFVIIa × 103, IU . | Follow-up, mo . |
|---|---|---|---|---|---|---|---|---|
| 1 | 28 | F | 57 | 1 | 10 | 0.16 | - | 48 |
| 2 | 31 | F | 70 | 1 | 8 | 0.15 | - | 85 |
| 3 | 31 | F | 328 | 1 | 25 | 0.25 | - | 86 |
| 4 | 31 | F | 170 | 1 | 16 | 0.33 | - | 36 |
| 5 | 40 | F | 153 | 1 | 14 | 0.12 | - | 58 |
| 6 | 54 | M | 205 | 1 | 18 | 0.23 | - | 36 |
| 7 | 79 | M | 20 | 1 | 13 | 0.089 | - | 49 |
| 8 | 70 | F | 128 | 1 | 14 | 0.315 | - | 48 |
| 9 | 71 | F | 89 | 1 | 16 | 0.13 | - | 48 |
| 10 | 63 | M | 760 | 1 | 60 | 0.96 | 30 | 76 |
| 11 | 75 | F | 22 | 1 | 17 | 0.14 | - | 74 |
| 12 | 70 | M | 38 | 1 | 12 | 0.15 | - | 51 |
| 13 | 73 | M | 159 | 1 | 18 | 0.12 | - | 55 |
| 14 | 68 | M | 327 | 1 | 17 | 0.1 | - | 58 |
| 15 | 67 | M | 274 | 1 | 18 | 0.21 | - | 62 |
| 16 | 71 | M | 164 | 1 | 11 | 0.075 | - | 58 |
| 17 | 76 | F | 295 | 1 | 17 | 0.127 | - | 34 |
| 18 | 81 | M | 263 | 1 | 20 | 0.024 | - | 44 |
| 19 | 65 | M | 430 | 1 | 55 | 0.36 | - | 12 |
| 20 | 65 | F | 380 | 1 | 30 | 0.71 | - | 12 |
| 21 | 48 | F | 173 | 1 | 20 | 0.25 | - | 34 |
| 22 | 70 | F | 89 | 1 | 13 | 0.26 | - | 36 |
| 23 | 79 | M | 480 | 1 | 47 | 0.41 | - | 50 |
| 24 | 50 | M | 75 | 1 | 14 | 0.028 | - | 54 |
| 25 | 61 | M | 3600 | 1 | 64 | 0.052 | - | 46 |
| 26 | 60 | F | 123 | 1 | 18 | 0.12 | - | 12 |
| 27 | 30 | F | 146 | 1 | 24 | 0.12 | - | 12 |
| 28 | 42 | F | 73 | 1 | 15 | 0.14 | - | 12 |
| 29 | 81 | F | 119 | 1 | 65 | 0.7 | - | 5 |
| 30 | 38 | M | 3550 | 1 | 68 | 1.87 | 15 | 24 |
| 31 | 79 | F | 15 | 1 | 40 | 0.43 | 2.2 | 12 |
| 32 | 65 | F | 35 | 1 | 35 | 0.06 | 11 | 36 |
| 33* | 79 | F | 85 | 1 (12) | 12 (155) | 0.1 (0.5) | - | 54 |
| 34*†‡ | 54 | M | 33 | 1 (14) | 14 (25) | 0.1 (0.23) | - | 54 |
| 35*‡ | 77 | F | 6 | 1 (27) | 23 (128) | 0.4 (0.4) | 12 | 15 |
Patient . | Age, y . | Sex . | Titer, BU . | Bleeding events . | Length of hospital stay, d . | FVIII × 106, IU . | rFVIIa × 103, IU . | Follow-up, mo . |
|---|---|---|---|---|---|---|---|---|
| 1 | 28 | F | 57 | 1 | 10 | 0.16 | - | 48 |
| 2 | 31 | F | 70 | 1 | 8 | 0.15 | - | 85 |
| 3 | 31 | F | 328 | 1 | 25 | 0.25 | - | 86 |
| 4 | 31 | F | 170 | 1 | 16 | 0.33 | - | 36 |
| 5 | 40 | F | 153 | 1 | 14 | 0.12 | - | 58 |
| 6 | 54 | M | 205 | 1 | 18 | 0.23 | - | 36 |
| 7 | 79 | M | 20 | 1 | 13 | 0.089 | - | 49 |
| 8 | 70 | F | 128 | 1 | 14 | 0.315 | - | 48 |
| 9 | 71 | F | 89 | 1 | 16 | 0.13 | - | 48 |
| 10 | 63 | M | 760 | 1 | 60 | 0.96 | 30 | 76 |
| 11 | 75 | F | 22 | 1 | 17 | 0.14 | - | 74 |
| 12 | 70 | M | 38 | 1 | 12 | 0.15 | - | 51 |
| 13 | 73 | M | 159 | 1 | 18 | 0.12 | - | 55 |
| 14 | 68 | M | 327 | 1 | 17 | 0.1 | - | 58 |
| 15 | 67 | M | 274 | 1 | 18 | 0.21 | - | 62 |
| 16 | 71 | M | 164 | 1 | 11 | 0.075 | - | 58 |
| 17 | 76 | F | 295 | 1 | 17 | 0.127 | - | 34 |
| 18 | 81 | M | 263 | 1 | 20 | 0.024 | - | 44 |
| 19 | 65 | M | 430 | 1 | 55 | 0.36 | - | 12 |
| 20 | 65 | F | 380 | 1 | 30 | 0.71 | - | 12 |
| 21 | 48 | F | 173 | 1 | 20 | 0.25 | - | 34 |
| 22 | 70 | F | 89 | 1 | 13 | 0.26 | - | 36 |
| 23 | 79 | M | 480 | 1 | 47 | 0.41 | - | 50 |
| 24 | 50 | M | 75 | 1 | 14 | 0.028 | - | 54 |
| 25 | 61 | M | 3600 | 1 | 64 | 0.052 | - | 46 |
| 26 | 60 | F | 123 | 1 | 18 | 0.12 | - | 12 |
| 27 | 30 | F | 146 | 1 | 24 | 0.12 | - | 12 |
| 28 | 42 | F | 73 | 1 | 15 | 0.14 | - | 12 |
| 29 | 81 | F | 119 | 1 | 65 | 0.7 | - | 5 |
| 30 | 38 | M | 3550 | 1 | 68 | 1.87 | 15 | 24 |
| 31 | 79 | F | 15 | 1 | 40 | 0.43 | 2.2 | 12 |
| 32 | 65 | F | 35 | 1 | 35 | 0.06 | 11 | 36 |
| 33* | 79 | F | 85 | 1 (12) | 12 (155) | 0.1 (0.5) | - | 54 |
| 34*†‡ | 54 | M | 33 | 1 (14) | 14 (25) | 0.1 (0.23) | - | 54 |
| 35*‡ | 77 | F | 6 | 1 (27) | 23 (128) | 0.4 (0.4) | 12 | 15 |
Total amount of factor substitution and previous conventional regimes are given for patients 33, 34, and 35. Values in parentheses are those obtained when patients underwent previous conventional treatment, as indicated by the symbols footnoted below. Patients 31, 32, and 35 had cancer. Patients 29, 31, 32, and 35 achieved PR under MBMP.
- indicates not given.
Corticosteroids, cyclophosphamide, immunoglobulin, azathioprine; FVIII substitution
Vincristine
FVIII inhibitor bypassing treatment (FEIBA)